

Dissociable Effects of Antipsychotics on Ketamine-Induced Changes in Regional Oxygenation and Inter-Regional Coherence of Low Frequency Oxygen Fluctuations in the Rat

Jennifer Li^{*1,4}, Keita Ishiwari^{1,2,4}, Michael W Conway¹, Jennifer Francois¹, John Huxter¹, John P Lowry², Adam J Schwarz³, Mark Tricklebank¹ and Gary Gilmour¹

¹Centre for Cognitive Neuroscience, Eli Lilly and Co. Limited, Windlesham, Surrey, UK; ²Department of Chemistry, National University of Ireland, Maynooth, Co. Kildare, Ireland; ³Tailored Therapeutics, Eli Lilly and Company, Indianapolis, IN, USA

Typical and atypical antipsychotics have been shown to alleviate N-methyl-D-aspartate (NMDA) receptor antagonist-induced BOLD signals in healthy humans and animals to differing degrees; factors that might relate to their different molecular mechanisms and clinical profiles. Recent studies have also extended these investigations to the analysis of resting state functional connectivity measures of BOLD signals in different brain regions. Using constant potential amperometry, we examined the effects of the NMDA receptor antagonist S-(+)-ketamine on tissue oxygen levels in medial prefrontal cortex (mPFC) and medial ventral striatum (mVS), and temporal coherence of low-frequency oxygen fluctuations between these regions in freely moving rats. Furthermore, we assessed the extent to which the atypical antipsychotic clozapine and the typical antipsychotic haloperidol could modulate the effects of S-(+)-ketamine on these measures. Acute S-(+)-ketamine (5–25 mg/kg) produced dose-dependent increases in both tissue O₂ levels and coherence. Although effects of clozapine and haloperidol alone were relatively minor, their effects on ketamine-induced signals were markedly more distinct. Clozapine dose-dependently attenuated the absolute S-(+)-ketamine (25 mg/kg) O₂ signal in both regions, and also attenuated ketamine-induced increases in regional coherence. Haloperidol had no effect on the absolute ketamine O₂ signal yet potentiated increases in regional coherence. The dissociable effects of haloperidol and clozapine on ketamine-induced hyperoxygenation and mPFC–mVS coherence elucidate potentially important mechanistic differences between these classes of pharmacology. This study demonstrates for the first time that *in vivo* amperometry can measure both regional brain tissue O₂ levels and inter-regional coherence, advancing BOLD-like measurements of functional connectivity into awake, unconstrained animals.

Neuropsychopharmacology (2014) **39**, 1635–1644; doi:10.1038/npp.2014.10; published online 12 February 2014

Keywords: constant potential amperometry; brain tissue oxygen; functional connectivity; coherence; ketamine; antipsychotics

INTRODUCTION

Brain imaging techniques have had substantial impact on neuroscience, for example, by highlighting regional and systems-level dysfunction of brain circuitry in neuropsychiatric disease. Pharmacological magnetic resonance imaging (phMRI) responses are widely used to probe disease-related pharmacology, for example, N-methyl-D-aspartate (NMDA) antagonist-induced brain activation as a model of schizophrenia and its modulation by antipsychotics (eg, Gozzi *et al*, 2008; Chin *et al*, 2011; Doyle *et al*, 2013). However, in this context, several studies have suggested that modulation of NMDA antagonist imaging signals by antipsychotics does not necessarily concur with

their effects on ‘psychotic’ symptoms (eg, Lahti *et al* 1995, Malhotra *et al*, 1996). Recently, novel imaging paradigms have shifted their focus to assessment of intrinsic brain activity to complement studies of evoked or event-related activity (Biswal *et al*, 1995; Fox and Raichle, 2007). Such studies have explored the notion of functional connectivity between brain regions using low-frequency BOLD fluctuation correlations, and abnormalities have been identified in resting-state connectivity in numerous diseases, including schizophrenia (for review, see Fox and Greicius, 2010). Assessment of functional connectivity via functional MRI (fMRI) in rodents is possible but is presently limited to anesthetized or heavily restrained animals (see review by Ferris *et al*, 2011), greatly limiting the scope of behavioral studies.

In-vivo oxygen amperometry is an alternative to rodent fMRI that can measure real-time changes in extracellular oxygen (O₂) in freely moving animals. This technique has been successfully used to measure regional brain tissue O₂ levels with sub-second temporal resolution in a variety of behavioral paradigms (McHugh *et al*, 2013; Francois *et al*,

*Correspondence: Dr J Li, Lilly Centre for Cognitive Neuroscience, Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK, Tel: +44 1276 483472, Fax: +44 1276 483525, E-mail: llije@lilly.com

⁴These authors contributed equally to this work.

Received 30 August 2013; revised 13 January 2014; accepted 14 January 2014; accepted article preview online 20 January 2014

2012; Howe *et al* 2013). Amperometric O₂ signals have been shown to be analogous to the fMRI BOLD signal (Lowry *et al*, 2010) and functionally related to discrete neuronal activation events (Li *et al*, 2011). Tissue O₂ signals also display low-frequency fluctuations similar to the BOLD signal, raising the possibility that analyses analogous to functional connectivity fMRI methods might be conducted in the conscious, behaving rodent by measuring correlations in these fluctuations between different brain areas.

Identification of resting-state networks and descriptions of their modification and dysfunction in disease states have encouraged cross-species study of pharmacological modulation of regional functional connectivity (Zhu *et al*, 2013; Gass *et al*, 2013), notably in the context of translational biomarkers of psychosis and antipsychotic efficacy. In this regard, the uncompetitive NMDA receptor antagonist ketamine (Anis *et al*, 1983; Lodge and Johnson, 1990) can be used in humans and animals to induce behavioral change bearing resemblance to psychosis (eg, Krystal *et al*, 1994; Malhotra *et al*, 1996, Moghaddam *et al*, 1997) that, in humans at least, concomitantly changes regional brain activity and coherence across different resting state networks. However, to date, there have been no studies looking at the effect of antipsychotics on ketamine-induced changes in functional connectivity in either species, hence both preclinical and clinical studies are needed to allow a translational mapping of cross-species effects. The aim of this study was to apply rat *in vivo* O₂ amperometry to allow simultaneous assessment of antipsychotic-induced modulation of S-(+)-ketamine-induced changes in prefrontal and ventral striatal regional activity and coherence, regions implicated in psychosis (Duncan *et al*, 1998b).

MATERIALS AND METHODS

Subjects

All experiments were conducted in accordance with the Animals (Scientific Procedures) Act 1986 and local ethical requirements of Eli Lilly. Twenty-two male Lister Hooded rats (300–400 g at surgery; Harlan, UK) were group-housed in a temperature-controlled (20–22 °C) environment with food and water available *ad libitum* under a 12-h light/12-h dark cycle for at least 7 days prior to surgical preparation. Following surgery, animals were singly housed under similar environmental conditions.

In Vivo Amperometry

Changes in extracellular tissue [O₂] were measured using constant potential amperometry with carbon paste electrodes (CPEs) (Lowry *et al*, 1997). A potential of –650 mV was applied to electrodes allowing the electrochemical reduction of dissolved O₂ at their tip (Lowry *et al*, 1996; Bolger *et al*, 2011). CPEs were constructed from 8 T (200 μm bare diameter, 270 μm coated diameter) Teflon-coated silver wire (Advent Research Materials, Suffolk, UK). The Teflon insulation was slid along the wire to create an ~2-mm deep cavity, which was packed with carbon paste (prepared according to O'Neill *et al*, 1982). Prior to implantation, all CPEs were calibrated *in vitro* in a glass cell containing 15 ml phosphate buffer solution (0.01 M), pH 7.4, saturated with

nitrogen (N₂) gas, atmospheric air (from a RENA air pump), or pure O₂ (compressed gas) at room temperature. The concentrations of dissolved O₂ were taken as 0 μM (N₂-saturated), 240 μM (air-saturated) (Foster *et al*, 1993), and 1260 μM (O₂-saturated) (Bourdillon *et al*, 1982), respectively. Reference and auxiliary electrodes were also prepared from 8 T Teflon-coated silver wire by removing 2 mm Teflon from the tip. All electrodes were soldered to gold connectors, which were cemented into six-pin plastic sockets (both from Plastic One, Roanoke, VA) during surgery.

Surgery

Under isoflurane anesthesia, animals were implanted bilaterally with CPEs in the medial prefrontal cortex (mPFC) (AP: +3.2 mm; ML: ±0.7 mm; DV: –4.2 mm from dura) and the medial ventral striatum (mVS) (AP: +1.9 mm; ML: ±0.8 mm; DV: –6.9 mm from dura). The reference electrode was placed in posterior cortex, and the auxiliary electrode was wrapped around one posterior skull screw. Pre- and post-operative Rimadyl (Carprofen 5 mg/kg sc; Pfizer) was administered, and animals were allowed to recover in thermostatically controlled cages. A post-operative period of 2 weeks was allowed before testing commenced.

Drugs

(S)-(+) -ketamine hydrochloride (Sigma-Aldrich, Gillingham, UK) was dissolved in 0.9% (w/v) saline, clozapine (Sigma-Aldrich) in a 50:50 mix of 0.1 M HCl and 0.9% (w/v) saline, and haloperidol (Tocris, Bristol, UK) initially in 1 M lactic acid (10% of total required) and brought up to volume with 0.9% (w/v) saline.

Testing Schedule

Animals were tested in Perspex test chambers (40 × 40 × 40 cm), where their head mounted six-pin socket was connected to a low-noise, four-channel potentiostat (Bio-stat, ACM Instruments, Cumbria, UK) via a flexible screened six-core cable mounted through a swivel (both Plastics One Roanoke, VA) in the ceiling of the cage. This arrangement allowed free movement of the animal throughout the cage. One hour before dosing, animals were placed individually in test chambers and a constant –650 mV potential applied to CPEs to allow signal settling. Both haloperidol (0.25, 0.5, 1 mg/kg ip) and clozapine (5, 10, 20 mg/kg ip) were dosed 30 min before injection of 25 mg/kg ketamine sc. Signals were recorded for 2 h after ketamine dosing, following which animals were returned to their home cages. Animals in each cohort randomly received each treatment condition per study, allowing at least 1 week between test sessions.

Data Recording and Processing

Amperometric recordings from each working electrode channel were recorded at 40 Hz, and a PowerLab 8/30 was used for analog/digital conversion before data were collected on a PC running Chart v5 (both AD Instruments, Oxford, UK). For each brain region (mVS and mPFC), one

hemisphere was chosen from each animal to be included in the analysis, which was determined based on visual inspection of noise level and signal quality. Post-collection, linear interpolation was used to replace occasional missing data points and a bi-quad Butterworth filter (high-pass 0.1 Hz) was used to suppress fast noise-related artifacts. Data were normalized by subtraction of the 60 s average pre-dose value from each data point in the series, thereby compensating for absolute differences in baselines between channels. Finally, a boxcar-averaging algorithm was applied to down-sample the data, keeping a single average from multiple 120 s non-overlapping windows.

Data Analysis

With regard to absolute regional signals, data were analyzed for 6800 s post-injection for the ketamine dose response study and 3600 s for all other studies. The full time course was shown for the ketamine dose response to show the time taken for the response to return to baseline levels, but given the peak of the response occurs within the first hour, all studies looking at the modulation of the ketamine response just shows the first 60 min. Area under the curve (AUC) was calculated according to the formula $AUC = (\sum_{t=0}^n a * d)$ where n = number of samples in the curve, a = current (nA) at a given sample and d = sample interval (120 s). For all studies, regional coherence data were analyzed in the 0.01–0.1 Hz range, from a period 300 s pre-dose to 1800 s post-dose, and averaged in 300 s time bins. To achieve this, the injection-aligned series of N data points from both brain regions were padded with $N/4$ additional points such that data trended toward zero rate of change. Padding helps to eliminate edge-artifacts which are produced when applying a low-pass filter to data with a mean offset from zero. Butterworth noise filtering was applied as before for each frequency F of interest and then data were correlated in a series of half-overlapping windows of length $2/F$, excluding padded sections of data. Pearson's r was generated as an index of coherence between the filtered signals at a given time for that frequency, to build a coherence spectrum over time for multiple frequency bins.

For absolute regional $[O_2]$ levels, AUC values were analyzed by a repeated measures ANOVA followed by Fisher's LSD *post hoc* test for multiple comparisons. For coherence analysis, broadband (0.1–0.01 Hz) correlation values (Pearson's r) were binned into 5 min time blocks, with one pre-dose time bin and six post-dose time bins. All r -values underwent Fisher's z -transformation before repeated measures ANOVA with treatment group and time-bin as within-subjects factors was performed. This is followed by Fisher's LSD *post hoc* test for multiple comparisons. Mauchly's sphericity test was performed on all coherence data and Greenhouse–Geisser adjustments applied to degrees of freedom as necessary.

Histology

Animals were deeply anaesthetized with pentobarbital and perfused transcardially with 0.9% (w/v) saline followed by 10% (w/v) buffered paraformaldehyde solution. Brains were removed and placed in 10% (w/v) buffered paraformaldehyde and shipped for histological processing (Neuroscience

Associates, Knoxville, TN), which involved 40 μ m coronal sectioning of implanted regions and staining with thionin for Nissl bodies. Upon return, microscopic assessment confirmed CPE placement with reference to a standard rat brain atlas (Paxinos and Watson, 2009). All inaccurate placements were excluded from subsequent analyses. The nucleus accumbans shell/core placements were pooled due to the low number of animals and lack of power to make a separate assessment. For coherence analysis, only animals with correctly placed electrodes and noise-free signals in both brain regions were included.

RESULTS

Histology

Figure 1 depicts photomicrographs of representative electrode placements in mPFC (Figure 1a) and mVS (Figure 1b), and reconstruction of all electrode placements (Figure 1c).

S-(+)-Ketamine dose Response Study

As shown in Figure 2, ketamine produced robust, dose-dependent increases in tissue $[O_2]$ in both regions as confirmed by significant main effects of dose on the AUC measure (mPFC: $F_{(3,21)} = 20.7$, $p < 0.001$; mVS: $F_{(3,15)} = 37.4$, $p < 0.001$). All doses of ketamine induced significant increases in AUC relative to the vehicle control (Figure 2b and d). In both regions, peak $[O_2]$ levels occurred within 6 min of dosing and higher doses produced progressively more sustained increases in $[O_2]$.

Figure 2e depicts coherograms of correlation strength across the 0.01–0.1 Hz range from -300 s to 1800 s post-injection for all treatment groups. Both time and dose-dependent changes in regional coherence are clearly evident from this figure. This data is summarized in figure 2f, where an averaged correlation of the frequency range of interest (0.01–0.1 Hz) for each treatment group is depicted in 5 min time bins. Following a Greenhouse–Geisser adjustment, a main effect of time ($F_{(3,3,23,2)} = 3.07$, $p = 0.044$) and *post hoc* analyses revealed a significant increase in coherence in the 10 mg/kg S-(+)-ketamine group between 5 and 25 min, and in the 25 mg/kg S-(+)-ketamine group between 5 and 15 min post-injection compared with the 5 min pre-injection baseline.

Clozapine and Haloperidol dose Response Studies

Clozapine caused a slight but significant attenuation of $[O_2]$ AUC in the mPFC (Figure 3a), where a significant main effect of dose was found ($F_{(3,15)} = 3.91$, $p = 0.03$), but not in the mVS (Figure 3b). Following *post-hoc* comparisons, all doses of clozapine were found to significantly decrease AUC relative to the vehicle control (all $p < 0.05$) in the mPFC. With regard to summarized regional coherence (Figure 3c), clozapine had little effect. The summarized data showed a significant main effect of time ($F_{(6,12)} = 3.58$, $p = 0.029$), but *post hoc* comparisons revealed only the 10 mg/kg clozapine group showed significant decreases in coherence at the 15–25 min time points relative to the pre-injection baseline ($p < 0.05$).




Figure 1 CPE placements. Photomicrographs of Nissl-stained sections showing the locus surrounding representative electrode placements in (a) medial prefrontal cortex and (b) ventromedial striatum. Scale bar, 1.0 mm. (c) Reconstruction of all electrode tip placements in medial prefrontal cortex and ventromedial striatum. Abbreviations: PrL, prelimbic cortex; IL, infralimbic cortex; CC, corpus callosum; NAc, nucleus accumbens; CPu, caudate putamen; LS, lateral septum; AC, anterior commissure. Figure generated from the Paxinos and Watson (2009) rat brain atlas.

AUC analyses showed significant effects of haloperidol dose in both regions (mPFC: $F_{(3,18)} = 3.45$, $p = 0.038$; mVS: $F_{(3,15)} = 3.97$, $p = 0.029$) where the 0.25 mg/kg dose significantly increased AUC in both regions compared with vehicle ($p < 0.01$) (Figure 3, lower panel). Similarly to clozapine, haloperidol also had little effect on regional $[O_2]$ coherence (Figure 3f), with only a trend toward a significant main effect of time following repeated measures ANOVA ($F_{(6,42)} = 2.16$, $p = 0.066$) observed ($n = 8$).

Clozapine—S-(+)-Ketamine Interaction Study

Time course data (Figure 4a and c) show that clozapine dose-dependently attenuated ketamine-induced increases in $[O_2]$ in both brain regions. This is confirmed by the AUC analysis which revealed a significant dose effect in the mPFC ($F_{(3,15)} = 32.86$, $p < 0.001$), where clozapine dose-dependently and significantly reduced $[O_2]$ at all doses tested (Figure 4b). In mVS, there was a trend toward an

effect of dose ($F_{(3,12)} = 3.44$, $p = 0.05$), where 20 mg/kg of clozapine significantly reduced $[O_2]$ AUC relative to ketamine alone in a *post hoc* comparison (Figure 4d). Frequency range \times time coherograms of ketamine for this study (Figure 4e) looked similar to those as observed in the ketamine dose response study, whereby increased regional $[O_2]$ coherence following ketamine treatment is evident. Thirty minutes pre-treatment with clozapine dose-dependently reduced this increase in $[O_2]$ coherence caused by ketamine, shown by the prominence of colder colors particularly in the 10 and 20 mg/kg clozapine-treated groups. These data are summarized in Figure 4f ($n = 6$). Following a significant dose \times time interaction ($F_{(18,90)} = 2.44$, $p = 0.003$) here, *post hoc* analyses first revealed a significant increase in coherence in the Veh/ket group between 5–20 min and 25–30 min post-injection, and also in the 5/Ket group at the 5–15 min post-injection time points compared with the 5 min pre-injection baseline ($-5-0$ min) (all $p < 0.05$). The 20 mg/kg dose of clozapine




Figure 2 Ketamine dose response study. (a) Temporal profile of changes in tissue O₂ levels following S-(+)-ketamine injection (5, 10, 25 mg/kg, s.c.) in mPFC ($n=8$) and (c) mVS ($n=6$). Means (\pm SEM) of normalized O₂ currents averaged over 2-min time bins are shown for the 2-h post-injection period. (b) mPFC and (d) mVS AUC measures extracted from the O₂ response, where bars represent mean (\pm SEM) AUC for the 2-h period following S-(+)-ketamine injection. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs vehicle. (e) Coherograms for each treatment group showing the correlation value (r) by color intensity at frequencies between 0.01 and 0.1 Hz (Y-axis) for -300 s pre-injection to 1800 s post-injection on the X-axis. (f) Summary of coherence data showing the correlation of the whole frequency range (0.01–0.1 Hz) for each treatment group in 5 min time bins ($n=8$). Bars represent mean (\pm SEM) Pearson correlation values (r) between 0.01 and 0.1 Hz in 5 min time blocks. RMANOVA performed on Fisher transformed r -values, and values quoted after a Greenhouse–Geisser correction. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs pre-injection baseline.

also showed a statistically significant decrease in coherence relative to the 5 min pre-injection baseline ($-5-0$ min) at 15–30 min time points (all $p < 0.05$). Compared with the Veh/Ket group, the 5 mg/kg dose of clozapine attenuated the ketamine coherence increase at the 15–25 min time points (both $p < 0.05$), whereas at doses of 10 mg/kg and 20 mg/kg clozapine pre-treatment significantly reduced ketamine-induced regional [O₂] coherence increases for the 5–30 min time points inclusive (all $p < 0.01$).

Haloperidol—S-(+)-Ketamine Interaction Study

Time course data (Figure 5a and c) show that haloperidol pre-treatment had little effect on the ketamine response in

both brain regions, and the AUC analyses for both regions (Figure 5b and d) revealed no significant effects following pre-treatment with haloperidol on ketamine-induced increases in regional [O₂] (all $F < 4$). Frequency range \times time coherograms (Figure 5e) confirmed a similar effect of ketamine alone to that observed in the ketamine dose response study with increases in regional [O₂] coherence observed following ketamine administration, but in this case haloperidol appeared to further increase coherence rather than decrease it. This was confirmed statistically in the summary analysis of coherence, as depicted in Figure 5f ($n=7$). Repeated-measures ANOVA showed a significant main effect of dose ($F_{(3,18)}=3.50$, $p=0.037$) and time ($F_{(6,36)}=14.25$, $p < 0.001$) but no dose \times time interaction




Figure 3 Clozapine and haloperidol dose response studies. Effect of clozapine injection (5, 10, 20 mg/kg, i.p.) on (a) mPFC ($n = 6$) and (b) mVS ($n = 6$) AUC measures extracted from the O_2 response, where bars represent mean (\pm SEM) AUC for the 1-h period following clozapine injection. (c) Summary of coherence data showing the correlation of the whole frequency range (0.01–0.1 Hz) for each treatment group in 5 min (300 s) time bins ($n = 5$). Bars represent mean (\pm SEM) Pearson correlation values (r) between 0.01 and 0.1 Hz in 5 min time blocks. The effect of haloperidol injection (0.25, 0.5, 1.0 mg/kg, i.p.) is shown for (d) mPFC ($n = 7$) and (e) mVS ($n = 6$) AUC measures extracted from the O_2 response, where bars represent mean (\pm SEM) AUC for the 1-h period following haloperidol injection. (f) Summary of coherence data showing the correlation of the whole frequency range (0.01–0.1 Hz) for each treatment group in 5 min (300 s) time bins ($n = 8$). Bars represent mean (\pm SEM) Pearson correlation values (r) between 0.01 and 0.1 Hz in 5 min time blocks. AUC: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs vehicle; Coherence: RMANOVAs performed on Fisher transformed r -values, * $p < 0.05$, ** $p < 0.01$, vs pre-injection baseline.

($F < 1$). For the Veh/Ket group, *post hoc* analyses confirmed significant increases in coherence at the 5–15 min and 20–25 min time points compared with the pre-injection baseline (all $p < 0.05$), in agreement with findings from the ketamine dose response study. Compared with Veh/Ket, haloperidol pre-treatment caused a significant enhancement of ketamine-induced increase in regional $[O_2]$ coherence following the 0.25 mg/kg dose at the 25–30 min time point, and the 0.5 mg/kg dose at the 10–20 min and 25–30 min time points.

DISCUSSION

This study demonstrates for the first time that it is possible to use *in vivo* O_2 amperometry to simultaneously measure absolute regional O_2 levels as well as regional coherence in low-frequency O_2 signal fluctuations in the awake behaving rat. Using this approach, we observed a ketamine-induced signal whereby absolute O_2 levels were dose-dependently increased in medial prefrontal cortical (mPFC) and ventral medial striatal (mVS) regions, together with an increased coherence of O_2 signal between these regions, consistent with effects previously observed in humans (eg, De Simoni et al, 2013; Driesen et al, 2013). Administration of haloperidol and clozapine had dissociable effects on ketamine-induced increases in oxygenation and coherence, in a manner that also replicated what has been observed in humans (Doyle et al, 2013). Although the mechanistic relevance of these findings is yet to be determined, combining measurement of regional absolute tissue O_2 levels with regional O_2 coherence opens up a range of

potential exploratory studies in rodents that might further define the predictive potential of these signals in humans.

Acute systemic administration of (S)-(+)-ketamine induced robust and sustained dose-related increases in tissue O_2 levels in both the mPFC and mVS of freely moving rats. Ketamine O_2 signals peaked rapidly in both brain sites, reflecting its known fast time course of action (Adams and Werner, 1997). The present results are in accordance with findings of past rodent glucose utilization studies (Duncan et al, 1998a, 1999; Miyamoto et al, 2000) and imaging studies (eg, Littlewood et al, 2006 and Chin et al, 2011) using ketamine and other NMDA receptor antagonists. Evidence of ketamine-induced neuronal activation also extends to neuroimaging markers in healthy humans (De Simoni et al, 2013; Deakin et al, 2008; Långsjö et al, 2003, 2004), suggesting an equivalent translational activation response of NMDA receptor antagonists across techniques and species. The present results also indicated increased mPFC–mVS inter-regional coherence of low-frequency oxygen oscillations following administration of S-(+)-ketamine. In human ketamine infusion studies, Driesen et al (2013) have shown increased global functional connectivity commensurate with psychotic symptoms in volunteers, and Anticevic et al (2012) demonstrated a disrupted reciprocal relationship between default mode and task-positive networks during the performance of a delayed working memory task. Although the present study did not incorporate behavioral assessment of animals, such studies are presently underway in our laboratories.

The effects of administration of clozapine and haloperidol were relatively small in contrast to the other findings




Figure 4 Clozapine–ketamine interaction study. (a) Temporal profile of changes in tissue O₂ levels in mPFC ($n=6$) and (c) mVSc ($n=5$) following (s)-(+)–ketamine (25 mg/kg, s.c.) injection in rats pre-treated with clozapine (5, 10, 20 mg/kg, i.p.). Means (\pm SEM) of normalized O₂ currents averaged over 2-min time bins are shown over the 1-h post-injection period. (b) mPFC and (d) mVSc AUC measures extracted from the O₂ response, where bars represent mean (\pm SEM) AUC for the 1-h period following ketamine injection. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs vehicle. (e) Coherograms for each treatment group showing the correlation value (r) by color intensity at frequencies between 0.01 and 0.1 Hz (Y-axis) for -300 s (5 min pre-injection) to 1800 s (30 min) post-ketamine injection on the X-axis. (f) Summary of coherence data showing the correlation of the whole frequency range (0.01–0.1 Hz) for each treatment group in 5 min (300 s) time bins ($n=6$). Bars represent mean (\pm SEM) Pearson correlation values (r) between 0.01 and 0.1 Hz in 5 min time blocks. RMANOVA performed on Fisher transformed r -values, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs pre-injection baseline; # $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$ vs Veh group.

reported here, remaining broadly in line with previous studies (Duncan *et al*, 1998a, Cochran *et al*, 2002, Wotanis *et al*, 2003). Clozapine and haloperidol also had minimal effect on mPFC–mVSc coherence when administered alone. Some recent imaging studies have also looked at the direct effect of various antipsychotics on resting-state fMRI in rodents (Gass *et al*, 2013) and schizophrenic patients (Sambataro *et al*, 2010; Bolding *et al*, 2012; Lui *et al*, 2010) with varying results. However, in terms of translational correspondence, this may be a particularly difficult literature to reconcile at present for several reasons. First in schizophrenic patients, baseline functional connectivity has

been shown to be altered (Fox and Greicius, 2010) such that investigations of antipsychotics may be confounded by variation in regional coherence in different patients from the outset. An important next step for preclinical research will be to determine whether proposed animal models of schizophrenia can consistently recapitulate any of these baseline differences in patients, as these models would then represent a more meaningful platform from which to study drug effects. Second, it is not clear at present how uniform and temporally stable such changes in functional connectivity are across the schizophrenic syndrome as a whole, and which resting state




Figure 5 Haloperidol–ketamine interaction study. (a) Temporal profile of changes in tissue O₂ levels in the mPFC ($n=6$) and (c) the mVSc ($n=5$) following S-(+)-ketamine (25 mg/kg, s.c.) injection in rats pre-treated with haloperidol (0.25, 0.5, 1.0 mg/kg, i.p.). Means (\pm SEM) of normalized O₂ currents averaged over 2-min time bins are shown over the 1-h post-injection period. (b) mPFC and (d) mVSc AUC measures extracted from the O₂ response, where bars represent mean (\pm SEM) AUC for the 1-h period following ketamine injection. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs vehicle. (e) Coherograms for each treatment group showing the correlation value (r) by color intensity at frequencies between 0.01 and 0.1 Hz (Y-axis) for -300 s (5 min pre-injection) to 1800 s (30 min) post-ketamine injection on the X-axis. (f) Summary of coherence data showing the correlation of the whole frequency range (0.01–0.1 Hz) for each treatment group in 5 min (300 s) time bins ($n=7$). Bars represent mean (\pm SEM) Pearson correlation values (r) between 0.01 and 0.1 Hz in 5 min time blocks. RMANOVA performed on Fisher transformed r -values, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs pre-injection baseline; # $p < 0.05$, ## $p < 0.01$, ### $p < 0.001$ vs Veh group.

network changes (and hence nodes to evaluate in animal studies) are the most relevant to specific symptoms and patient outcome.

Compared with their rather meager effects on baseline measurements in rats, clozapine, and haloperidol had marked and differential effects on regional [O₂] and mPFC–mVSc coherence induced by ketamine. Most notably, clozapine (5–20 mg/kg) produced significant dose-dependent suppression of ketamine-induced increases in both regions, and also attenuated ketamine-induced increases in mPFC–mVSc coherence. In contrast, haloperidol (0.25–1.0 mg/kg)

did not significantly modulate [O₂] following ketamine administration, and potentiated mPFC–mVSc coherence over and above the increase induced by ketamine alone. The regional [O₂] observations presented here are in line with previous findings using other techniques. For instance, Duncan *et al* (1998a) showed in rats that increases in 2-DG uptake induced by 30 mg/kg of ketamine were normalized by clozapine (5–10 mg/kg) in all brain regions studied, whereas a 0.5 mg/kg dose of haloperidol potentiated ketamine-induced activation of 2-DG uptake. A pHMRI study in anesthetized rats (Gozzi *et al*, 2008) has also shown that acute

administration of PCP (0.5 mg/kg, i.v.) produced robust and sustained increases in relative cerebral blood volume (rCBV) in discrete cortico-limbo-thalamic regions, and that clozapine (5 mg/kg) completely suppressed PCP-induced rCBV responses in the thalamus and less so in cortical and hippocampal structures, whereas raclopride (0.3 mg/kg), a dopamine D₂ antagonist similar to haloperidol, did not affect the PCP-induced increases in rCBV. This study also demonstrated no effects of clozapine or raclopride *per se* on rCBV, broadly consistent with our present findings. More recently, a phMRI study in healthy human volunteers described attenuation of the BOLD signal increase induced by ketamine challenge by the atypical antipsychotic risperidone and the anticonvulsant lamotrigine (Doyle *et al*, 2013).

Importantly, differential effects on mPFC–mVS coherence were observed, where clozapine attenuated ketamine-induced increases in mPFC–mVS coherence, but haloperidol enhanced this coherence. To date, there are no known rsfMRI studies describing the effect of antipsychotics on an NMDA receptor antagonist-induced modulation of functional connectivity—this will be a crucial translational comparison to be conducted. Future preclinical O₂ amperometry work also needs to measure from various other nodes in resting state networks, first to more precisely define the extent to which these networks are homologous to those described in humans, but also to show that this indeed is a phenomenon specific to restricted nodes and not simply a global, non-specific effect. As physiological changes such as heart rate or blood pressure were not recorded in this study, their contribution to coherence levels cannot be determined. However, unpublished data from this lab shows that different combinations of brain regions in the same animal show different levels of coherence, suggesting that high coherence at rest is not a global response caused by a physiological artifact of this technique. The simultaneous measurement of other physiological parameters and behaviors such as locomotor activity will also help rule out the possibility of artifactual confound of functional connectivity measures. Although we have shown a clear differential effect of clozapine and haloperidol on ketamine-induced changes in activation and functional connectivity, the mechanistic interpretation of this effect needs to be further investigated. Studies that compare the hemodynamic response to direct measures of neuronal activity such as EEG/LFP recordings under the influence of this pharmacology, as well as measuring behavioral responses, would help elucidate the functional significance of these findings.

It is undoubtedly premature to assign a functional significance to the differences in regional amperometric O₂ levels and inter-regional coherence effects, yet the present results demonstrate differential responses of typical and atypical antipsychotics on NMDA antagonist-induced brain activation and functional connectivity. These results fit well with existing literature on phMRI and rsfMRI responses described already, and lay the foundation for experiments analogous to functional connectivity imaging methods to be conducted in awake, behaving animals. This holds great promise for the development of a novel translational bridging technology to better define cross-species biomarkers for drug research and functional assays for neuroscience research in general.

FUNDING AND DISCLOSURE

JL, MWC, JF, JH, AJS, MT and GG are employees of Eli Lilly and Co. Ltd. KI was financially supported by Eli Lilly and Co. Ltd. The remaining authors declare no conflict of interest.

ACKNOWLEDGEMENTS

JPL acknowledges the financial support of NUI Maynooth, Enterprise Ireland (CFTD/2008/107), Science Foundation Ireland (03/IN3/B376S), and Eli Lilly and Co. Limited. KI acknowledges the support of NUI Maynooth.

REFERENCES

- Adams HA, Werner C (1997). From the racemate to the eutomer: (S)-ketamine. Renaissance of a substance? *Anaesthetist* **46**: 1026–1042.
- Anis NA, Berry SC, Burton NR, Lodge D (1983). The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. *Br J Pharmacol* **79**: 565–575.
- Anticevic A, Gancsos M, Murray JD, Repovs G, Driesen NR, Ennis DJ *et al* (2012). NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. *PNAS* **109**: 16720–16725.
- Biswal B, Yetkin FZ, Haughton VM, Hyde JS (1995). Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. *Magn Reson Med* **34**: 537–541.
- Bolding MS, White DM, Hadley JA, Weiler M, Holcomb HH, Lahti AC (2012). Antipsychotic drugs alter functional connectivity between the medial frontal cortex, hippocampus, and nucleus accumbens as measured by H2150 PET. *Front Psychiatry* **3**: 105.
- Bolger FB, McHugh SB, Bennett R, Li J, Ishiwari K, Francois J *et al* (2011). Characterisation of carbon paste electrodes for real-time amperometric monitoring of brain tissue oxygen. *J Neurosci Methods* **195**: 135–142.
- Bourdillon C, Thomas V, Thomas D (1982). Electrochemical study of D-glucose oxidase autoinactivation. *Enzyme Microb Technol* **4**: 175–180.
- Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M *et al* (2011). Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. *J Pharmacol Exp Ther* **336**: 709–715.
- Cochran SM, McKerchar CE, Morris BJ, Pratt JA (2002). Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol. *Neuropharmacology* **43**: 394–407.
- Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM (2008). Glutamate and the neural basis of the subjective effects of ketamine: a pharmacological magnetic resonance imaging study. *Arch Gen Psychiatry* **65**: 154–164.
- De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C *et al* (2013). Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. *Neuroimage* **64**: 75–90.
- Doyle OM, De Simoni S, Schwarz AJ, Brittain C, O'Daly OG, Williams SC *et al* (2013). Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents. *J Pharmacol Exp Ther* **345**: 151–160.
- Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC *et al* (2013). Relationship of resting brain

- hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. *Mol Psychiatry* 18: 1199–1204.
- Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998a). Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. *Brain Res* 812: 65–75.
- Duncan GE, Moy SS, Knapp DJ, Mueller RA, Breese GR (1998b). Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. *Brain Res* 787: 181–190.
- Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (1999). Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. *Brain Res* 843: 171–183.
- Ferris CF, Smerkers B, Kulkarni P, Caffrey M, Afacan O, Toddes S et al (2011). Functional magnetic resonance imaging in awake animals. *Rev Neurosci* 22: 665–674.
- Foster TH, Hartley DF, Nichols MG, Hilf R (1993). Fluence rate effects in photodynamic therapy of multicell tumor spheroids. *Cancer Res* 53: 1249–1254.
- Fox MD, Greicius M (2010). Clinical applications of resting state functional connectivity. *Front Syst Neurosci* 4: 19.
- Fox MD, Raichle ME (2007). Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. *Nat Rev Neurosci* 8: 700–711.
- Francois J, Conway MW, Lowry JP, Tricklebank MD, Gilmour G (2012). Changes in reward-related signals in the rat nucleus accumbens measured by in vivo oxygen amperometry are consistent with fMRI BOLD responses in man. *Neuroimage* 60: 2169–2181.
- Gass N, Schwarz AJ, Sartorius A, Cleppien D, Zheng L, Schenker E et al (2013). Haloperidol modulates mid-brain-prefrontal functional connectivity in the rat brain. *Eur Neuropsychopharmacol* 23: 1310–1319.
- Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, Bifone A (2008). Differential effects of antipsychotic and glutamatergic agents on the pHMRI response to phencyclidine. *Neuropsychopharmacology* 33: 1690–1703.
- Hitchman ML (1978). *Measurement of Dissolved Oxygen*, Vol. 49 (Krieger Publishing Company).
- Howe WM, Berry AS, Francois J, Gilmour G, Carp JM, Tricklebank M et al (2013). Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans. *J Neurosci* 33: 8742–8752.
- Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. *Arch Gen Psychiatry* 51: 199–214.
- Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. *Neuropsychopharmacology* 13: 9–19.
- Långsjö JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V et al (2003). Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. *Anesthesiology* 99: 614–623.
- Långsjö JW, Salmi E, Kaisti KK, Aalto S, Hinkka S, Aantaa R et al (2004). Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. *Anesthesiology* 100: 1065–1071.
- Li J, Bravo DS, Upton AL, Gilmour G, Tricklebank MD, Fillenz M et al (2011). Close temporal coupling of neuronal activity and tissue oxygen responses in rodent whisker barrel cortex. *Eur J Neurosci* 34: 1983–1996.
- Littlewood CL, Jones N, O'Neill MJ, Mitchell SN, Tricklebank M, Williams SC (2006). Mapping the central effects of ketamine in the rat using pharmacological MRI. *Psychopharmacology (Berl)* 186: 64–81.
- Lodge D, Johnson KM (1990). Noncompetitive excitatory amino acid receptor antagonists. *Trends Pharmacol Sci* 11: 81–86.
- Lowry JP, Boutelle MG, Fillenz M (1997). Measurement of brain tissue oxygen at a carbon paste electrode can serve as an index of increases in regional cerebral blood flow. *J Neurosci Methods* 71: 177–182.
- Lowry JP, Boutelle MG, O'Neill RD, Fillenz M (1996). Characterization of carbon paste electrodes in vitro for simultaneous amperometric measurement of changes in oxygen and ascorbic acid concentrations in vivo. *Analyst* 121: 761–766.
- Lowry JP, Griffin K, McHugh SB, Lowe AS, Tricklebank M, Sibson NR (2010). Real-time electrochemical monitoring of brain tissue oxygen: a surrogate for functional magnetic resonance imaging in rodents. *Neuroimage* 52: 549–555.
- Lui S, Li T, Deng W, Jiang L, Wu Q, Tang H et al (2010). Short-term effects of antipsychotic treatment on cerebral function in drug-naïve first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. *Arch. Gen Psychiatry* 67: 783–792.
- Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. *Neuropsychopharmacology* 14: 301–307.
- McHugh SB, Marques-Smith A, Li J, Rawlins JN, Lowry J, Conway M et al (2013). Hemodynamic responses in amygdala and hippocampus distinguish between aversive and neutral cues during Pavlovian fear conditioning in behaving rats. *Eur J Neurosci* 37: 498–507.
- Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. *J Neurosci* 17: 2921–2927.
- Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE (2000). Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. *Neuropsychopharmacology* 22: 400–412.
- O'Neill RD, Grunewald RA, Fillenz M, Albery WJ (1982). Linear sweep voltammetry with carbon paste electrodes in the rat striatum. *Neuroscience* 7: 1945–1954.
- Paxinos G, Watson C (2009). *The Rat Brain in Stereotaxic Coordinates*. 6th edn, Elsevier.
- Sambataro F, Blasi G, Fazio L, Caforio G, Taurisano P, Romano R et al (2010). Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia. *Neuropsychopharmacology* 35: 904–912.
- Wotanis J, Hanak SE, Wettstein JG, Black MD (2003). Comparative analysis of acute and chronic administration of haloperidol and clozapine using [³H] 2-deoxyglucose metabolic mapping. *Schizophr Res* 61: 195–205.
- Zhu Y, Gao B, Hua J, Liu W, Deng Y, Zhang L et al (2013). Effects of methylphenidate on resting-state brain activity in normal adults: an fMRI study. *Neurosci Bull* 29: 16–27.